Compare Biogen Inc (BIIB) vs Chipotle Mexican Grill, Inc. (CMG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Chipotle Mexican Grill, Inc. — how do they compare? Biogen Inc trades at $206.51 (market cap $30.13B), while Chipotle Mexican Grill, Inc. trades at $32.73 (market cap $40.49B). The key difference: Chipotle Mexican Grill, Inc. is the larger of the two by market cap, and Biogen Inc is trading nearer its 52-week high, Chipotle Mexican Grill, Inc. nearer its low. Which is the better fit depends on your goals.
| BIIB | CMG | |
|---|---|---|
Market Cap | $30.13B | $40.49B |
Sector | Health | Consumer Cyclical |
52-Week High | $216.63 | $44.04 |
52-Week Low | $128.93 | $28.17 |
Enterprise Value | $37.20B | $45.24B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $206.48, down 0.31% on the day, with a bullish technical signal supported by moving averages. The company reported Q2 2026 EPS of $3.60, beating estimates of $2.94, and raised full-year guidance, driven by growth in Alzheimer's and rare disease portfolios. Recent acquisitions like RayThera and Apellis bolster its pipeline. Revenue for 2025 was $9.89 billion with a net income margin of 13.07%, though margins have fluctuated year-over-year.
Outlook remains positive with strong analyst support (62.5% buy rating) and a consensus price target of $234.47, implying ~14% upside. Key risks include reliance on new drug launches to offset declining multiple sclerosis sales and integration challenges from acquisitions. Cash flow trends show variability, with 2026 projecting negative net cash flow due to significant investing activities.
CMG trades at $32.71, up 1.76% on the day, with a bearish technical signal driven by moving averages. The company reported strong revenue growth to $11.93B in 2025 and has consistently beaten EPS estimates in recent quarters. However, net cash flow turned negative at -$392M due to aggressive financing activities. Recent news highlights a salmonella outbreak linked to jalapeños, creating near-term headwinds.
Wall Street maintains a bullish stance with a $42.17 consensus price target, representing 29% upside, and no sell ratings. Key risks include food safety issues, margin compression, and negative cash flow. The stock's high P/E of 29.63 requires sustained earnings growth to justify valuation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Chipotle Mexican Grill, Inc.
Chipotle Mexican Grill is the largest fast-casual chain restaurant in the United States, with systemwide sales of $7.5 billion in 2021. The Mexican concept is entirely company-owned, with a footprint of more than 3,000 stores, heavily indexed to the United States (though the firm maintains a small presence in Canada, the U.K., France, and Germany). Chipotle sells burritos, burrito bowls, tacos, quesadillas, and beverages, with a selling proposition built around competitive prices, high-quality food sourcing, speed of service, and convenience. The company generates its revenue entirely from restaurant sales and delivery fees.
Read more on CMG →
